Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China
Objectives. Several species of rapidly growing mycobacteria (RGM) are now recognized as human pathogens. However, limited data on effective drug treatments against these organisms exists. Here, we describe the species distribution and drug susceptibility profiles of RGM clinical isolates collected f...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2015-01, Vol.2015 (2015), p.1-8 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 2015 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2015 |
| creator | Wan, Kanglin Liu, Haican Zhao, Xiuqin Li, Guilian Pang, Hui Yu, Ping |
| description | Objectives. Several species of rapidly growing mycobacteria (RGM) are now recognized as human pathogens. However, limited data on effective drug treatments against these organisms exists. Here, we describe the species distribution and drug susceptibility profiles of RGM clinical isolates collected from four southern Chinese provinces from January 2005 to December 2012. Methods. Clinical isolates (73) were subjected to in vitro testing with 31 antimicrobial agents using the cation-adjusted Mueller-Hinton broth microdilution method. The isolates included 55 M. abscessus, 11 M. fortuitum, 3 M. chelonae, 2 M. neoaurum, and 2 M. septicum isolates. Results. M. abscessus (75.34%) and M. fortuitum (15.07%), the most common species, exhibited greater antibiotic resistance than the other three species. The isolates had low resistance to amikacin, linezolid, and tigecycline, and high resistance to first-line antituberculous agents, amoxicillin-clavulanic acid, rifapentine, dapsone, thioacetazone, and pasiniazid. M. abscessus and M. fortuitum were highly resistant to ofloxacin and rifabutin, respectively. The isolates showed moderate resistance to the other antimicrobial agents. Conclusions. Our results suggest that tigecycline, linezolid, clofazimine, and cefmetazole are appropriate choices for M. abscessus infections. Capreomycin, sulfamethoxazole, tigecycline, clofazimine, and cefmetazole are potentially good choices for M. fortuitum infections. Our drug susceptibility data should be useful to clinicians. |
| doi_str_mv | 10.1155/2015/419392 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4550772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A458161398</galeid><sourcerecordid>A458161398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-ce7437b5dca5af45561b201ddaf05e25602e4c19f65354a6ef59da627387fb083</originalsourceid><addsrcrecordid>eNqNks1r3DAQxUVpaEKaU-9F0EtJ2Ubfti-FZZumgYRAm57FWJYcLba1leyG_e8js-k2zSm6SKAfb2bePITeUfKZUinPGKHyTNCKV-wVOmKcioWigr7evzk_RCcprUk-JVWkUm_QIVNcUsX5EVp_jVOLf07J2M3oa9_5cYtvbRr90OLgMKd4OYy-9yaG2kOHl60dxoTDgH_AxjfdFl_EcD_T11sTajCjjR7wZQodjDZhF0OPV3d-gLfowEGX7MnjfYx-fTu_XX1fXN1cXK6WVwsjKzEujC0EL2rZGJDghJSK1nnKpgFHpGVSEWaFoZVTkksByjpZNaBYwcvC1aTkx-jLTncz1b1tTO43Qqc30fcQtzqA1___DP5Ot-GPzrVIUbAs8PFRIIbfU_ZC9z7703Uw2DAlTQvKZEkJKV6Ckqpkpaoy-uEZug5THLITmSKKqoIL_o9qobPaDy7kFs0sqpciF80LreYRP-2ovJWUonX76SjRcy70nAu9y0Wm3z81ZM_-TUEGTndAXlMD9_5lajYj1sETWErBGH8AWCbHrQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706167343</pqid></control><display><type>article</type><title>Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wan, Kanglin ; Liu, Haican ; Zhao, Xiuqin ; Li, Guilian ; Pang, Hui ; Yu, Ping</creator><contributor>Omri, Abdelwahab</contributor><creatorcontrib>Wan, Kanglin ; Liu, Haican ; Zhao, Xiuqin ; Li, Guilian ; Pang, Hui ; Yu, Ping ; Omri, Abdelwahab</creatorcontrib><description>Objectives. Several species of rapidly growing mycobacteria (RGM) are now recognized as human pathogens. However, limited data on effective drug treatments against these organisms exists. Here, we describe the species distribution and drug susceptibility profiles of RGM clinical isolates collected from four southern Chinese provinces from January 2005 to December 2012. Methods. Clinical isolates (73) were subjected to in vitro testing with 31 antimicrobial agents using the cation-adjusted Mueller-Hinton broth microdilution method. The isolates included 55 M. abscessus, 11 M. fortuitum, 3 M. chelonae, 2 M. neoaurum, and 2 M. septicum isolates. Results. M. abscessus (75.34%) and M. fortuitum (15.07%), the most common species, exhibited greater antibiotic resistance than the other three species. The isolates had low resistance to amikacin, linezolid, and tigecycline, and high resistance to first-line antituberculous agents, amoxicillin-clavulanic acid, rifapentine, dapsone, thioacetazone, and pasiniazid. M. abscessus and M. fortuitum were highly resistant to ofloxacin and rifabutin, respectively. The isolates showed moderate resistance to the other antimicrobial agents. Conclusions. Our results suggest that tigecycline, linezolid, clofazimine, and cefmetazole are appropriate choices for M. abscessus infections. Capreomycin, sulfamethoxazole, tigecycline, clofazimine, and cefmetazole are potentially good choices for M. fortuitum infections. Our drug susceptibility data should be useful to clinicians.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2015/419392</identifier><identifier>PMID: 26351633</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Anti-infective agents ; Anti-Infective Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; China ; Disease prevention ; Dosage and administration ; Drug dosages ; Drug interactions ; Drug Resistance, Bacterial - drug effects ; Health aspects ; Humans ; Immunology ; Infections ; Infectious diseases ; Microbial Sensitivity Tests - methods ; Mycobacteria ; Mycobacterium ; Mycobacterium - drug effects ; Mycobacterium - isolation & purification ; Mycobacterium Infections - drug therapy ; Mycobacterium Infections - microbiology ; Observations ; Studies</subject><ispartof>BioMed research international, 2015-01, Vol.2015 (2015), p.1-8</ispartof><rights>Copyright © 2015 Hui Pang et al.</rights><rights>COPYRIGHT 2015 John Wiley & Sons, Inc.</rights><rights>Copyright © 2015 Hui Pang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2015 Hui Pang et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-ce7437b5dca5af45561b201ddaf05e25602e4c19f65354a6ef59da627387fb083</citedby><cites>FETCH-LOGICAL-c594t-ce7437b5dca5af45561b201ddaf05e25602e4c19f65354a6ef59da627387fb083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550772/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550772/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26351633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Omri, Abdelwahab</contributor><creatorcontrib>Wan, Kanglin</creatorcontrib><creatorcontrib>Liu, Haican</creatorcontrib><creatorcontrib>Zhao, Xiuqin</creatorcontrib><creatorcontrib>Li, Guilian</creatorcontrib><creatorcontrib>Pang, Hui</creatorcontrib><creatorcontrib>Yu, Ping</creatorcontrib><title>Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Objectives. Several species of rapidly growing mycobacteria (RGM) are now recognized as human pathogens. However, limited data on effective drug treatments against these organisms exists. Here, we describe the species distribution and drug susceptibility profiles of RGM clinical isolates collected from four southern Chinese provinces from January 2005 to December 2012. Methods. Clinical isolates (73) were subjected to in vitro testing with 31 antimicrobial agents using the cation-adjusted Mueller-Hinton broth microdilution method. The isolates included 55 M. abscessus, 11 M. fortuitum, 3 M. chelonae, 2 M. neoaurum, and 2 M. septicum isolates. Results. M. abscessus (75.34%) and M. fortuitum (15.07%), the most common species, exhibited greater antibiotic resistance than the other three species. The isolates had low resistance to amikacin, linezolid, and tigecycline, and high resistance to first-line antituberculous agents, amoxicillin-clavulanic acid, rifapentine, dapsone, thioacetazone, and pasiniazid. M. abscessus and M. fortuitum were highly resistant to ofloxacin and rifabutin, respectively. The isolates showed moderate resistance to the other antimicrobial agents. Conclusions. Our results suggest that tigecycline, linezolid, clofazimine, and cefmetazole are appropriate choices for M. abscessus infections. Capreomycin, sulfamethoxazole, tigecycline, clofazimine, and cefmetazole are potentially good choices for M. fortuitum infections. Our drug susceptibility data should be useful to clinicians.</description><subject>Anti-infective agents</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>China</subject><subject>Disease prevention</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug interactions</subject><subject>Drug Resistance, Bacterial - drug effects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Microbial Sensitivity Tests - methods</subject><subject>Mycobacteria</subject><subject>Mycobacterium</subject><subject>Mycobacterium - drug effects</subject><subject>Mycobacterium - isolation & purification</subject><subject>Mycobacterium Infections - drug therapy</subject><subject>Mycobacterium Infections - microbiology</subject><subject>Observations</subject><subject>Studies</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNks1r3DAQxUVpaEKaU-9F0EtJ2Ubfti-FZZumgYRAm57FWJYcLba1leyG_e8js-k2zSm6SKAfb2bePITeUfKZUinPGKHyTNCKV-wVOmKcioWigr7evzk_RCcprUk-JVWkUm_QIVNcUsX5EVp_jVOLf07J2M3oa9_5cYtvbRr90OLgMKd4OYy-9yaG2kOHl60dxoTDgH_AxjfdFl_EcD_T11sTajCjjR7wZQodjDZhF0OPV3d-gLfowEGX7MnjfYx-fTu_XX1fXN1cXK6WVwsjKzEujC0EL2rZGJDghJSK1nnKpgFHpGVSEWaFoZVTkksByjpZNaBYwcvC1aTkx-jLTncz1b1tTO43Qqc30fcQtzqA1___DP5Ot-GPzrVIUbAs8PFRIIbfU_ZC9z7703Uw2DAlTQvKZEkJKV6Ckqpkpaoy-uEZug5THLITmSKKqoIL_o9qobPaDy7kFs0sqpciF80LreYRP-2ovJWUonX76SjRcy70nAu9y0Wm3z81ZM_-TUEGTndAXlMD9_5lajYj1sETWErBGH8AWCbHrQ</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Wan, Kanglin</creator><creator>Liu, Haican</creator><creator>Zhao, Xiuqin</creator><creator>Li, Guilian</creator><creator>Pang, Hui</creator><creator>Yu, Ping</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China</title><author>Wan, Kanglin ; Liu, Haican ; Zhao, Xiuqin ; Li, Guilian ; Pang, Hui ; Yu, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-ce7437b5dca5af45561b201ddaf05e25602e4c19f65354a6ef59da627387fb083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-infective agents</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>China</topic><topic>Disease prevention</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug interactions</topic><topic>Drug Resistance, Bacterial - drug effects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Microbial Sensitivity Tests - methods</topic><topic>Mycobacteria</topic><topic>Mycobacterium</topic><topic>Mycobacterium - drug effects</topic><topic>Mycobacterium - isolation & purification</topic><topic>Mycobacterium Infections - drug therapy</topic><topic>Mycobacterium Infections - microbiology</topic><topic>Observations</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wan, Kanglin</creatorcontrib><creatorcontrib>Liu, Haican</creatorcontrib><creatorcontrib>Zhao, Xiuqin</creatorcontrib><creatorcontrib>Li, Guilian</creatorcontrib><creatorcontrib>Pang, Hui</creatorcontrib><creatorcontrib>Yu, Ping</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wan, Kanglin</au><au>Liu, Haican</au><au>Zhao, Xiuqin</au><au>Li, Guilian</au><au>Pang, Hui</au><au>Yu, Ping</au><au>Omri, Abdelwahab</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>2015</volume><issue>2015</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Objectives. Several species of rapidly growing mycobacteria (RGM) are now recognized as human pathogens. However, limited data on effective drug treatments against these organisms exists. Here, we describe the species distribution and drug susceptibility profiles of RGM clinical isolates collected from four southern Chinese provinces from January 2005 to December 2012. Methods. Clinical isolates (73) were subjected to in vitro testing with 31 antimicrobial agents using the cation-adjusted Mueller-Hinton broth microdilution method. The isolates included 55 M. abscessus, 11 M. fortuitum, 3 M. chelonae, 2 M. neoaurum, and 2 M. septicum isolates. Results. M. abscessus (75.34%) and M. fortuitum (15.07%), the most common species, exhibited greater antibiotic resistance than the other three species. The isolates had low resistance to amikacin, linezolid, and tigecycline, and high resistance to first-line antituberculous agents, amoxicillin-clavulanic acid, rifapentine, dapsone, thioacetazone, and pasiniazid. M. abscessus and M. fortuitum were highly resistant to ofloxacin and rifabutin, respectively. The isolates showed moderate resistance to the other antimicrobial agents. Conclusions. Our results suggest that tigecycline, linezolid, clofazimine, and cefmetazole are appropriate choices for M. abscessus infections. Capreomycin, sulfamethoxazole, tigecycline, clofazimine, and cefmetazole are potentially good choices for M. fortuitum infections. Our drug susceptibility data should be useful to clinicians.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>26351633</pmid><doi>10.1155/2015/419392</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2015-01, Vol.2015 (2015), p.1-8 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4550772 |
| source | MEDLINE; PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Anti-infective agents Anti-Infective Agents - therapeutic use Antibiotics Antimicrobial agents China Disease prevention Dosage and administration Drug dosages Drug interactions Drug Resistance, Bacterial - drug effects Health aspects Humans Immunology Infections Infectious diseases Microbial Sensitivity Tests - methods Mycobacteria Mycobacterium Mycobacterium - drug effects Mycobacterium - isolation & purification Mycobacterium Infections - drug therapy Mycobacterium Infections - microbiology Observations Studies |
| title | Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T05%3A10%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20Susceptibility%20Testing%20of%2031%20Antimicrobial%20Agents%20on%20Rapidly%20Growing%20Mycobacteria%20Isolates%20from%20China&rft.jtitle=BioMed%20research%20international&rft.au=Wan,%20Kanglin&rft.date=2015-01-01&rft.volume=2015&rft.issue=2015&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2015/419392&rft_dat=%3Cgale_pubme%3EA458161398%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706167343&rft_id=info:pmid/26351633&rft_galeid=A458161398&rfr_iscdi=true |